Table 1.
Clinical characteristics of AbP subjects in the whole cohort and separate data sets
| Characteristic | Progressors | Nonprogressors | P value |
|---|---|---|---|
| Total | |||
| Sample size (n) | 39 | 65 | |
| Age at sampling (years) | 7.41 (1.74–15.02) | 9.05 (1.55–45.08) | 4.07E-04 |
| Age at first AbP (years) | 3.48 (0.77–12.56) | 7.28 (0.84–40.78) | 1.79E-05 |
| Follow-up time (years) | 5.64 (0.21–12.12) | 8.9 (5.5–16.35) | 6.77E-08 |
| Male sex | 22 (56.41) | 34 (52.31) | 0.84 |
| FDR | 23 (58.97) | 27 (41.54) | 0.13 |
| Genetic risk (H/M/L/unknown) | 19/7/12/1 | 16/16/30/3 | 2.12E-02 |
| ≥2 AbP | 31 (79.49) | 24 (36.92) | 6.15E-05 |
| Interval time* | 2.60 ± 2.44 | 1.66 ± 1.94 | 3.32E-02 |
| Microarray data set | |||
| Sample size (n) | 21 | 15 | |
| Age at sampling (years) | 7.66 (1.74–10.56) | 7.86 (2.25–15.18) | 0.34 |
| Age at first AbP (years) | 3.15 (0.77–9.77) | 4.53 (0.84–13.46) | 0.12 |
| Follow-up time (years) | 6.12 (0.21–11.41) | 8.38 (6.23–16.35) | 2.09E-03 |
| Male sex | 9 (43) | 8 (53.33) | 0.78 |
| FDR | 10 (48) | 8 (53.33) | 1.00 |
| Genetic risk (H/M/L/unknown) | 11/5/5/0 | 4/5/6/0 | 0.23 |
| ≥2 AbP | 20 (95) | 14 (93.33) | 1.00 |
| Interval time* | 2.59 ± 2.48 | 1.94 ± 2.16 | 0.42 |
| RT-PCR data set | |||
| Sample size (n) | 18 | 50 | |
| Age at sampling (years) | 7.22 (3.48–15.02) | 9.68 (1.55–45.08) | 1.82E-03 |
| Age at first AbP (years) | 4.02 (0.81–12.56) | 8.95 (1.3–40.78) | 1.75E-04 |
| Follow-up time (years) | 4.6 (2.48–12.12) | 9.2 (5.5–15.65) | 2.46E-04 |
| Male sex | 13 (72.22) | 26 (52) | 0.23 |
| FDR | 13 (72.22) | 19 (38) | 2.65E-02 |
| Genetic risk (H/M/L/unknown) | 8/2/7/1 | 12/11/24/3 | 0.18 |
| ≥2 AbP | 11 (61.11) | 10 (20) | 3.28E-03 |
| Interval time* | 2.60 ± 2.55 | 1.57 ± 1.88 | 0.07 |
Data are median (range), n (%), and mean ± SD unless otherwise indicated. H, high; L, low; M, medium.
*
Time between first antibody detection and collection of the sample tested.